Nu-3 Gel for Infected Diabetic Foot Ulcers

Launched by LAKEWOOD-AMEDEX INC · Aug 27, 2023

Keywords

ClinConnect Summary

This clinical trial is testing a new gel, called Nu-3, to see if it helps improve mild infections in diabetic foot ulcers. The main goals are to find out the right strength of the gel and how often it should be applied to help heal the infection. Participants in the study will apply the gel to their foot ulcer either once or twice a day for two weeks and will need to keep weight off that foot during this time. Some participants will receive the actual gel, while others will receive a placebo, which looks like the gel but contains no active ingredients.

To join the trial, you need to be at least 18 years old and have a mild infection in a specific type of foot ulcer related to diabetes. Your ulcer should be small and not too deep, and you should be able to manage your care at home. You’ll also need to have someone who can help you with the treatment process. The study is not recruiting participants yet, but if you're interested, it could be a valuable opportunity to explore a new treatment option for diabetic foot infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male and female subjects ≥18 years of age. 2. Voluntary written informed consent, including information about the provisions of the Health Insurance Portability and accountability act (HIPAA) as applicable.
• • 3. Non-hospitalized ambulatory subjects diagnosed with diabetes mellitus, Type I or II per ADA criteria with signs of a localized mild foot infection as defined by the IDSA infection severity criteria (Lipsky,2012)
• • a. the presence of purulent drainage or at least two of the following criteria: i. erythema, ii. warmth, iii. pain or tenderness, iv. edema, or v. induration (The diagnosis of mild infection must be confirmed immediately following debridement at Baseline).
• • 4. The target ulcer is classified as a grade 1 ulcer according to the Wagner Scale (Wagner 1979). The ulcer is a superficial, full-thickness ulcer limited to the dermis, not extending to the subcutis. Target ulcer is \>1 cm2 and \<12 cm2 post debridement at baseline and must be no higher than the ankle, on or below the malleolus (ankle bone) with ≥50% below the malleolus.
• 5. Adequate vascular perfusion as evidenced by one of the following:
• • 1. Dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 40 mmHg
• • 2. Ankle Branchial Index (ABI) between 0.9 and 1.3 within 3 months of Screening using the extremity with the target ulcer.
• • 3. Arterial Doppler ultrasound evaluating for biphasic or triphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of \>0.75.
• • 6. Subject has a caregiver who will attend the Baseline visit (V2) and/or watch the dosing and dressing demonstration video and apply wound treatment along with study dressings for the study duration.
• 7. Must meet one of the following criteria:
• • a. Female subjects of Non-Child-Bearing Potential i. Postmenopausal for at least 1 year ii. Surgically sterilized (i.e., hysterectomy or bilateral oophorectomy more than 3 months prior to Screening) iii. Bilateral tube ligation \> 6 months prior to screening iv. A negative serum β-hCG pregnancy test at screening and no breastfeeding after the administration of the study drug.
• • b. Male subjects of Non-Childbearing Potential defined as: i. Vasectomized subjects for \> 6 months prior to Screening ii. Those diagnosed as sterile by a physician. c. Females and Males of Childbearing Potential who practice an acceptable method of contraception defined as the i. Use of any form of hormonal contraceptive ii. Use of a barrier method with spermicide, condoms, intrauterine device, iii. Abstinence from sexual intercourse starting at least 60 days prior to Screening and continuing at least 14 days following the last treatment.
• • 8. Subjects must be willing to undergo all clinical investigation-related procedures, attend all required visits, and cooperate fully with the investigator and site personnel.
• • 9. Subject must be willing to wear offloading RCW, if necessary, throughout the duration of the clinical treatment.
• • 10. Subject must have plain radiograph taken at screening and prior to randomization showing no evidence of bony abnormalities consistent with osteomyelitis, or gas compatible with tissue crepitus, in the affected foot.
• Exclusion Criteria:
• • 1. Ulceration with exposed tendon, capsule, or bone 2. IDSA-defined moderate or severe DFU infection. 3. Infected diabetic foot ulcer that is associated with local wound complication such as prosthetic materials or protruding surgical hardware.
• • 4. \> 1 infected foot ulcer 5. Subject is currently receiving topical antimicrobial treatment for a localized infection of the study ulcer and whose infection is improving in response to treatment.
• • 6. Subject has received a systemic antibiotic within 48 hours prior to Screening.
• • 7. Concurrent or expected to require systemic antimicrobials during the study period for any infection including diabetic foot ulcer.
• • 8. Any subject that has active viral hepatitis (A, B, C) and/or untreated HIV/AIDS.
• • 9. Any subject that has vascular compromise requiring surgical intervention or has undergone vascular reconstruction or angioplasty less than 1 month prior to randomization. Any planned surgical procedures during the study participation 10. eGFR \<60 and/or subject on hemodialysis within 3 months prior to randomization.
• • 11. Hemoglobin A1c (HbA1c) \>12% within 3 months prior to randomization. 12. Aspartate Aminotransferase (AST, GOT) and/or Alanine Aminotransferase (ALT, GPT) \>3.0 x the upper limit of normal and/or bilirubin \>1.5 x the upper limit of normal within 3 months prior to randomization.
• • 13. Acute active Charcot foot 14. Any subject that would be unable to safely monitor the infection status at home and return for scheduled visits.
• • 15. History of immunosuppression within 3 months prior to randomization, or taking immunosuppressive agents including systemic corticosteroids, except stable daily doses of 5 mg/day or less for chronic conditions 16. Any subject with a life expectancy ≤ 6 months 17. Use of investigational drugs within 28 days prior to screening 18. Use of Aspirin® or acetylsalicylic acid containing medication (except low-dose aspirin) \< 7 days before baseline, 19. Use of oral anticoagulants (e.g., warfarin, Xarelto® or comparable products).
• • 20. History of concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol including known or suspected active abuse of alcohol, narcotics, or non-prescription drugs.
• • 21. Prior randomization in this clinical trial, or a previous Bisphosphocin study